Pre-earnings brief
Reports
Wed, Nov 3, 2010
Est. EPS
—
Est. revenue
—
Implied move
±13.0%
EPS beat rate
13%
Cogent Biosciences, Inc. is a biotechnology company focused on developing treatments for serious diseases. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as the demand for innovative therapies grows.
Last quarter
In Q3 2024, Cogent reported an EPS of -$0.64, missing estimates by 17%. The stock reacted slightly negatively, dropping 0.19% the following day.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-13.59%
Avg 1-day reaction
+3.32%
Investors are cautiously optimistic about Cogent's upcoming earnings, especially given the company's history of missing EPS estimates but still seeing stock price increases afterward.
Bull case
If Cogent can show improved cost management and a clearer path to revenue growth, it could significantly boost investor confidence and stock price.
Bear case
Continued misses on EPS and unclear revenue projections could lead to further declines in stock price, especially if investor sentiment turns negative.
The print will turn on these.
Q1
What will be the EPS figure for Q4-2024?
Given the company's history of missing EPS estimates, this figure will be crucial for assessing financial health and investor confidence.
Q2
What is the outlook for revenue growth moving forward?
A clear revenue growth forecast will be essential for investors to gauge the company's future potential and market position.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may underestimate the potential for Cogent to improve its cost structure and revenue generation, leading to a more favorable outlook than currently anticipated.
Supporting evidence
Despite recent misses, the stock has shown resilience with positive reactions in the days following earnings.
The options market is pricing a larger move than historically realized, indicating heightened expectations.
The company's innovative pipeline could yield unexpected positive results not reflected in current estimates.
Key risk
If the company can demonstrate a clear path to profitability, it could shift investor sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a series of misses, and investors are looking for signs of recovery.
Bull confirmed if
A positive EPS surprise of at least 10% would confirm the bull case.
Bear confirmed if
An EPS miss greater than 20% would confirm the bear case.
What the market is pricing for the move.
Implied Move
±21.5%
Historical Avg
±3.4%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±13.0% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
33.5%
Smart-money positioning from the most recent 13F filings.
Institutional
103.29%
of float
Insider
0.29%
of float
Holders
362
institutions
Top Holders· as of Dec 2025
FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cogent beats expectations, history suggests a +2.45% move, confirming a positive outlook for the company.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity.
Miss
A significant miss could lead to a decline of around +3.44%, reflecting ongoing concerns about the company's financial health.
The lines on the call that would change the story.
Blackrock Inc.
12,974,591 sh · $477.6M
7.99%
25.1%
Vanguard Group Inc
11,514,326 sh · $423.8M
7.09%
48.4%
Deerfield Management Company, L.P
9,043,903 sh · $332.9M
5.57%
-0.1%
Fairmount Funds Management LLC
9,003,418 sh · $331.4M
5.55%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.